Patients with simple steatosis who have not yet progressed to MASH lack approved pharmacological options, and current clinical management primarily depends on lifestyle modification, which is often limited by poor adherence and inconsistent therapeutic outcomes
J Biol Chem 281:1506415072 Divakaruni AS, Wallace M, Buren C, Martyniuk K, Andreyev AY, Li E, Fields JA, Cordes T, Reynolds IJ, Bloodgood BL, Raymond LA, Metallo CM, Murphy AN (2017) Inhibition of the mitochondrial pyruvate carrier protects from excitotoxic neuronal death
The early phase isn't the full story Clinical data indicates that initial symptom relief can begin in 2 to 4 weeks , but full efficacy for social fear/anxiety and avoidance often requires the full 12-week trial period, especially in off-label use for social anxiety, as described in this summary of Lexapro's timeline in social anxiety
Vy liu lng v tc dng ph th sao